<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01512004</url>
  </required_header>
  <id_info>
    <org_study_id>LEES-MIC</org_study_id>
    <nct_id>NCT01512004</nct_id>
  </id_info>
  <brief_title>Propiverine Hydrochloride Extended-Release Capsule for Overactive Bladder</brief_title>
  <official_title>Phase III Study of Propiverine Hydrochloride Extended-Release Capsule in the Treatment of Overactive Bladder (OAB) in Chinese Population With Urgent Micturition, Frequent Micturition and/or Urge Urinary Incontinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lee's Pharmaceutical Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>APOGEPHA Arzneimittel GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lee's Pharmaceutical Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Phase III study is to evaluate the efficacy and safety of Propiverine
      Hydrochloride Extended-Release Capsule in the treatment of overactive bladder in Chinese
      population with urgent micturition, frequent micturition and/or urge urinary incontinence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, randomized, doubled-blind, double dummy clinical study, in comparison
      with Tolterodine Tartrate Extended-Release Tablet as active parallel control to evaluate the
      efficacy and safety of Propiverine Hydrochloride Extended-Release Capsule in the treatment of
      Overactive Bladder in Chinese population with urgent micturition, frequent micturition and/or
      urge urinary incontinence.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alteration of mean micturition frequency within 24h on the basis of continuous 3-day record</measure>
    <time_frame>prior to medication and 8 weeks after medication</time_frame>
    <description>The voiding frequency per 24 hours, and the alteration of mean micturition frequency within 24 hours on the basis of continuous 3-day record, prior to medication and 8 weeks after medication</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The alteration of mean incontinence frequency and mean micturition frequency and volume within 24 hours on the basis of continuous 3-day record</measure>
    <time_frame>prior to medication, 2 weeks and 8 weeks after medication</time_frame>
    <description>The alteration of mean incontinence frequency, mean micturition frequency and volume within 24 hous on the basis of continuous 3-day record,prior to medication, 2 weeks and 8 weeks after medication. Additionaly, to evaluate the subject's feeling of treatment benefit and the time of the drug effect onset.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">324</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Propiverine Hydrochloride Extended-Release Capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 mg/capsule; oral; once per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tolterodine Extended-release Tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4mg/tablet; oral; once per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propiverine Hydrochloride</intervention_name>
    <description>drug of oral capsule</description>
    <arm_group_label>Propiverine Hydrochloride Extended-Release Capsule</arm_group_label>
    <other_name>Mictonorm</other_name>
    <other_name>Propierine Hydrochloride Extended-Release Capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolterodine Extended-release Tablet</intervention_name>
    <description>4mg/tablet; oral; once per day</description>
    <arm_group_label>Tolterodine Extended-release Tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18 to 65, male or female patient has a diagnosis of overactive bladder and the
             symptoms of OAB&gt;3 months subject has urinary frequency (average micturition frequency
             within 24h&gt;8 times), urgency and/or urge incontinence by micturition diary card during
             screening period

          -  Mean volume of single micturition is less than 200ml by micturition diary dard during
             screening period

          -  The subject is willing and able to complete the micturition diary card correctly

          -  Subject's urine routine test show that he/she has no urinary tract infection Subject
             signs informed consent form

        Exclusion Criteria:

          -  Confirmed by the investigator that subject has severe stress incontinence.

          -  Subject who has serious heart disease or arrhythmia, in the investigator's opinion, is
             not suitable to enroll.

          -  Subject who has contraindications of anticholinergic therapy, such as urinary
             retention, gastric retention and uncontrollable angle closure glaucoma.

          -  Subject who has a symptomatic acute urinary tract infection.

          -  Subject who has a recurrent urinary tract infection.

          -  Subject who has interstitial cystitis.

          -  Subject who has an agnogenic hematuria.

          -  Subject who has a bladder outlet obstruction of clinical significance.

          -  Subject who needs retention catheterization or intermittent catheterization.

          -  Patient with malignant tumor.

          -  Subject who has received anticholinergic drugs or other drugs for treating OAB within
             washout period, or who will receive these drugs after this study begins.

          -  Subject who is pregnant or lactating, or plans to be pregnant subject who has received
             other clinical study drugs or its participating in other clinical trial within 30
             days.

          -  Women of childbearing age who has not taken sufficient contraception measures within 3
             months before random number distribution; or intends to stop the contraception
             measures during the trial or within one month after the treatment is over.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin Li, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Lee's Pharmaceutical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Chaoyang Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2010</study_first_submitted>
  <study_first_submitted_qc>January 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2012</study_first_posted>
  <last_update_submitted>January 24, 2012</last_update_submitted>
  <last_update_submitted_qc>January 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Overactive Bladder</keyword>
  <keyword>urgent micturition</keyword>
  <keyword>frequent micturition</keyword>
  <keyword>urge urinary incontinence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
    <mesh_term>Urinary Incontinence, Urge</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolterodine Tartrate</mesh_term>
    <mesh_term>Propiverine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

